DJIA 17,907.61 102.81 0.58%
NASDAQ 4,775.04 9.66 0.20%
S&P 500 2,074.19 3.54 0.17%
market minute promo

AstraZeneca plc (ADR) (NYSE: AZN)

72.24 0.55 (0.77%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

AZN $72.24 0.77%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $72.72
Previous Close $71.69
Daily Range $71.72 - $72.73
52-Week Range $58.29 - $82.68
Market Cap $91.2B
P/E Ratio 35.14
Dividend (Yield) $1.80 (3.9%)
Ex-Dividend Date
Dividend Pay Date
08/13/14
09/15/14
Volume 788,962
Average Daily Volume 1,828,393
Current FY EPS $4.41

Sector

Healthcare

Industry

Drugs

AstraZeneca plc (ADR) (AZN) Description

The Company discovers, develops, manufactures and markets prescription pharmaceuticals for important areas of healthcare: cancer, cardiovascular, gastrointestinal, infection, neuroscience, and respiratory and inflammation. Website: http://www.astrazeneca.com/

News & Commentary Rss Feed

3 Drugmakers Facing a Pivotal 2015

Isis Pharmaceuticals, PTC Therapeutics, and GW Pharmaceuticals all expect 2015 to be a pivotal year in their drive toward becoming commercially viable entities. Should investors jump in before the catalysts spark?

Buying These 3 Stocks Is Like Making a Bet in a Burning House

Aegerion Pharmaceuticals, MannKind Corp., and VIVUS, Inc. have all attracted short sellers in droves this year. With each company facing serious headwinds, should investors avoid these struggling biotechs?

The Most Disappointing Clinical Failures in 2014

Three Motley Fool contributors tell us what they think were the biggest drug trial failures this year.

Update: In A Surprise Twist, AstraZeneca Wins Accelerated FDA Approval For Lynparza

Why Is George Soros Buying This Beaten Down Biotech Stock?

Soros Fund Management opened a position in the struggling biotech Aegerion Pharmaceuticals in the third quarter, even while the drugmaker's revenue estimates continued to plummet. Should retail investors follow his lead into this beaten down biotech?

Drug Giants Face $65 Billion in Lost Sales as Insurers Attack Patents

Expiring patents on major brand name drugs, particularly bipolar treatments and other prescriptions for central nervous system disorders, may cost $65 billion in lost sales by 2019, a new study shows.

A New Study on Diabetes Reveals Potentially Frightening News

Diabetes affects 29.1 million people in the United States, and is a dangerous long-term disease in its own right. This latest study, however, could add another aspect for diabetics to worry about.

AstraZeneca's Lynparza Approved in EU for Ovarian Cancer - Analyst Blog

Update: AstraZeneca Wins EU Approval For Lynparza

Tax Inversions Wrap Up

See More AZN News...

AZN's Top Competitors

AZN $72.24 (0.77%)
Current stock: AZN
JNJ $106.50 (0.90%)
Current stock: JNJ
NVS $95.19 (0.61%)
Current stock: NVS
RHHBY $34.71 (0.70%)
Current stock: RHHBY